Risk Assessment of "Other Substances" – L-Carnitine and L-Carnitine-L-tartrate

Bruzell, Ellen; Granum, Berit; Hetland, Ragna Bogen; Husøy, Trine; Rohloff, Jens; Wicklund, Trude; Steffensen, Inger‐Lise

doi:10.9734/ejnfs/2018/42545

Cited by 2 publications

(4 citation statements)

References 25 publications

(39 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The National Health & Medical Research Council have not considered a DRI for L-carnitine, because it is a non-essential nutrient [ 35 ]. Since 2 g/day of L-carnitine has been reported as “the upper level for supplements” in risk assessment studies, this human tolerance level of L-carnitine will be recommended [ 36 , 37 ].…”

Section: Discussionmentioning

confidence: 99%

L-Carnitine’s Effect on the Biomarkers of Metabolic Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

2020

View full text Add to dashboard Cite

A systematic review and meta-analysis of randomized controlled trials (RCTs) was carried out to assess L-carnitine supplements’ influence on the biomarkers of metabolic syndrome (MetSyn). PubMed, EMBASE, Cochrane library, and CINAHL were used to collect RCT studies published prior to February 2020. RCT studies were included if they had at least one of the following biomarker outcome measurements: waist circumference (WC), blood pressure (BP), fasting blood sugar (FBS), triglyceride (TG), or high density lipoprotein-cholesterol (HDLc). Nine of twenty studies with adequate methodological quality were included in this meta-analysis. The dose of L-carnitine supplementation administered varied between 0.75 and 3 g/day for durations of 8–24 weeks. L-carnitine supplementation significantly reduced WC and systolic BP (SBP), with no significant effects on FBS, TG, and HDLc. We found that L-carnitine supplementation at a dose of more than 1 g/d significantly reduced FBS and TG and increased HDLc. In conclusion, L-carnitine supplementation is correlated with a significant reduction of WC and BP. A dose of 1–3 g/d could improve the biomarkers of MetSyn by reducing FBS and TG and increasing HDLc.

show abstract

Section: Discussionmentioning

confidence: 99%

L-Carnitine’s Effect on the Biomarkers of Metabolic Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

2020

View full text Add to dashboard Cite

show abstract

“…По данным норвежских исследователей, потребление L-карнитина с традиционным рационом без использования обогащенных им пищевых продуктов и БАД к пище составляет 100-300 мг/сут [7]. По данным французских исследователей, суточное поступление L-карнитина с обычным рационом составляет около 77 мг, причем 77,8% приходится на мясные продукты и 14,4% -на молочные продукты и яйца [8].…”

Section: практикаunclassified

“…Вместе с тем верхний безопасный уровень суточного потребления L-карнитина для взрослых составляет 2000 мг (29 мг на 1 кг массы тела) [7,46], согласно рекомендациям Норвежского научного комитета по безопасности пищевых продуктов -1 500 мг (или 2 250 мг в виде тартрата) [7]. Испанское агентство по безопасности пищевых продуктов и питанию ограничивает суточный прием добавок L-карнитина или L-карнитина гидрохлорида до 2 000 мг, L-карнитина тартрата -до 3 000 мг 3 .…”

Section: практикаunclassified

See 1 more Smart Citation

L-carnitine: food sources, adequate and clinically effective doses

Kodentsova,

Risnik,

Kryukova

et al. 2024

Medicinskij sovet

View full text Add to dashboard Cite

L-carnitine plays a key role in cell bioenergetics, it belongs to vitamin-like substances, but unlike vitamins, it not only comes from food, but is also synthesized in the body. Endogenous synthesis decreases with age, under certain physiological conditions, taking medications. In this regard, specialized food products (SFP) and food supplements are being developed, containing L-carnitine as one of the functional ingredients. Comparison of doses of L-carnitine approved for use in biologically active food supplements and specialized food products with doses that provide a clinical effect.A review of existing literature on this issue in recent years was carried out using the RSCI, Pubmed databases and in the Google Scholar, ResearchGate systems. The amount of L-carnitine contained in a daily portion of SPP is established by domestic regulatory documents based on an adequate level of daily intake for adults, which is 300 mg and the upper permissible level of daily intake in the composition of SFP and food supplements is 900 mg/day. Reception of L-carnitine 1–2 g per day. within 5–12 weeks led to an increase in its concentration in the blood plasma, and also improved the indicators of the antioxidant status. Long-term intake of L-carnitine in doses of 2–3 g in patients with dyslipidemia, type 2 diabetes (DM2) and cardiovascular diseased (CVD) led to an improvement in the lipid profile of blood plasma, glycemic control, and had an anti-inflammatory effect. The condition for achieving a clinical effect in patients is long-term use and high doses. The intake of physiological doses of L-carnitine is appropriate for individuals from risk groups. Clinically effective doses of L-carnitine, when used for at least 12 weeks, correspond to or are 2 times higher than the upper permissible intake level in the composition of SPP and dietary supplements.

show abstract

Risk Assessment of "Other Substances" – L-Carnitine and L-Carnitine-L-tartrate

Cited by 2 publications

References 25 publications

L-Carnitine’s Effect on the Biomarkers of Metabolic Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

L-Carnitine’s Effect on the Biomarkers of Metabolic Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

L-carnitine: food sources, adequate and clinically effective doses

Contact Info

Product

Resources

About